2003D-0570 - Guidance for Industry: GUIDANCE FOR THE CLINICAL EVALUATION OF WEIGHT- CONTROL DRUGS; Availability
FDA Comment Number : EC4
Submitter : Dr. Christian Weyer Date & Time: 05/03/2004 05:05:36
Organization : Amylin Pharmaceuticals, Inc.
Drug Industry
Category :
Issue Areas/Comments
GENERAL
GENERAL
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and cardiovascular disease. The companys mission is to improve the lives of people with diabetes and other metabolic diseases through the discovery, development, and commercialization of innovative, cost-effective medicines. Because of its ongoing research in and commitment to obesity and obesity-related diseases, Amylin welcomes the opportunity to comment on the FDA draft guidance titled, Guidance for the Clinical Evaluation of Weight-Control Drugs.